Source: Optimi Health
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Optimi Health (OPTI) has finalized three new Canadian retail and e-commerce distribution agreements for its Optimi Life nutraceutical mushroom products
  • After its online launch of its mushroom supplements online in February, the company made agreements with Well.ca, Vitasave, and Healthy Planet to sell its line of functional mushroom supplements
  • Optimi Health (OPTI) is down 3.80 per cent trading at C$0.38 as of 10:00 am ET

Optimi Health (OPTI) has finalized three new Canadian retail and e-commerce distribution agreements for its Optimi Life nutraceutical mushroom products.

After its online launch of its mushroom supplements online in February, the company made agreements with Well.ca, Vitasave, and Healthy Planet to sell its line of functional mushroom supplements.

Well.ca is a natural foods e-commerce platform, while Vitasave has two retail outlets and an e-commerce platform, and Healthy Planet has a web-based selling platform as well as more than 30 retail locations across Ontario.

Optimi CEO, Bill Ciprick, said the agreements strengthen the company’s business-to-business distribution network and positions the Optimi Life brand for expansion into international markets.

“With the global functional mushroom market estimated to grow 9.5 per cent annually over the next six years, we’ll be actively positioning the Optimi Life brand throughout Canada as well as in international markets.”

Optimi Health (OPTI) is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets

Optimi Health (OPTI) is down 3.80 per cent trading at C$0.38 as of 10:00 am ET.


More From The Market Herald

" BetterLife Pharma (CSE:BETR) closes private placement

BetterLife Pharma (BETR) has closed a non-brokered private placement for gross proceeds of $474,000.

" Red Light Holland (CSE:TRIP) utilizing 3D movement data for psychedelic therapy

Red Light Holland (TRIP) subsidiary Radix Motion has received an International Preliminary Report on Patentability on the patent application filed in 2020. ...

" Algernon (CSE:AGN) receives FDA Orphan Drug Designation for Ifenprodil to treat Idiopathic Pulmonary Fibrosis

Algernon Pharmaceuticals (AGN) has been granted Orphan Drug Designation (ODD) for Ifenprodil to treat Idiopathic Pulmonary Fibrosis (IPF).